Benitec Biopharma Inc.BNTCEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Benitec Biopharma Limited is an Australian biotechnology company founded in 1997. It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference (ddRNAi) technology.
BNTC Q2 FY2026 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-13.4M
Net Profit
$-11.8M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.26
Benitec Biopharma Inc. Q2 FY2026 Financial Summary
Benitec Biopharma Inc. reported revenue of $0 for Q2 FY2026, with a net profit of $-11.8M (down 60.9% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-11.8M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q2 FY2026 |
Benitec Biopharma Inc. Annual Revenue by Year
Benitec Biopharma Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $0).
Benitec Biopharma Inc. Quarterly Revenue & Net Profit History
Benitec Biopharma Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2026 | $0 | — | $-11.8M | N/A |
| Q1 FY2026 | $0 | — | $-9.0M | N/A |
| Q3 FY2025 | $0 | — | $-9.4M | N/A |
| Q2 FY2025 | $0 | — | $-9.6M | N/A |
| Q1 FY2025 | $0 | — | $-5.1M | N/A |
| Q4 FY2024 | $0 | — | $-4.7M | N/A |
| Q3 FY2024 | $0 | — | $-4.3M | N/A |
| Q2 FY2024 | $0 | — | $-6.8M | N/A |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $21.4M | $15.0M | $52.2M | $68.8M | $79.1M | $105.2M | $96.0M | $190.7M |
| Liabilities | $5.9M | $3.5M | $5.0M | $4.6M | $3.1M | $7.6M | $2.4M | $3.3M |
| Equity | $15.5M | $11.5M | $47.2M | $64.2M | $75.9M | $97.6M | $93.6M | $187.4M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.4M | $-6.2M | $-3.3M | $-4.6M | $-7.7M | $-3.1M | $-3.4M | $-3.8M |